Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig plus pumitamig with or without chemotherapy for extensive-stage small cell lung cancer
NL-OMON61771Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of obrixtamig, pumitamig and carboplatin in small cell lung cancer (SCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment-emergent adverse events leading to trial medication discontinuation or dose modification. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
obrixtamigpumitamigcarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON61771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61771.